The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > REGULATORY
REGULATORY
- CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 7, 2011
- MHLW Senior Vice Minister Tsuji, Parliamentary Secretary Fujita in Charge of Medical, Nursing Fee Revision
September 7, 2011
- Dr Kondo of PMDA Presents Example of Successful Use of Regulatory Science
September 6, 2011
- Pharmaceutical Industry Fully Sufficient as Export Industry: METI Minister Hachiro
September 5, 2011
- MHLW Minister Komiyama to Focus on Social Security Reform
September 5, 2011
- Noda Cabinet: MHLW Vice Minister Komiyama Promoted to Minister
September 5, 2011
- Make the Premium for New Drug Development Permanent: FPMAJ, PhRMA, EFPIA Japan
September 5, 2011
- Increases in Social Security Spending to Be Covered by Cuts in Other Spending: FY2012 Budget
September 5, 2011
- US FDA Approves Vemurafenib for Melanoma; to Be Copromoted by Daiichi Sankyo
September 5, 2011
- Patent Office to Revise GL for Application of Patent Extension System
September 5, 2011
- Korosho to Apply for PIC/S Membership in Early FY2012: New CND Director Nakaigawa
September 5, 2011
- New EAD Director Kamata Supports Making Premium for New Drug Development Permanent
September 5, 2011
- METI to Establish New Company to Support Medical Tourism from Overseas
September 5, 2011
- Avastin Recommended for Approval for Breast Cancer
September 5, 2011
- Fingolimod Recommended for Approval
September 5, 2011
- Almarl or Amaryl Should Be Renamed to Prevent Mistakes: MHLW
September 1, 2011
- Anticancer Drug Dispensed Instead of Norvasc Generic: MHLW Report
September 1, 2011
- Upgrading Quality Both in Facilities, Research for ICH-GCP: RDD Director Sahara
September 1, 2011
ページ
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…